Professor Daniel Aberdam says : “Our work represents an important step forward, but necessitates standardization of the methodology to reach market and clinics. It could take some times. We plan within the next years to provide “ready to use” graftable cornea derived from patient hairs. Such product will be highly valuable as cellular models to test occular toxicity of drugs and cosmetological products, instead of animal testing . ”
Professor Daniel Aberdam just received the Grand Prix Fondation Générale de Santé for cell therapy and regenerative medicine 2013 of the Academy of Sciences. The awarded work has been developed in his laboratory at Inserm (former Unit 898) which is associated with the Technion (Israel), Professor Aberdam being the director of both teams. “Thanks to both Inserm and Technion, my team could carry out our research ,” he says.
For Israel Info Science, Professor Aberdam marks another step forward for which he received this prestigious award, “even if the media have focused on the production of corneal cells, our work also relates to a rare disease, ectodermal dysplasia due to a mutation inthe gene p63. Patients lose their sight because their cornea becomes opaque. My team and I have identified a molecule capable of repairing cultured corneal cells we have derived from the patient hairs. The next step is to include the molecule in eye drops to treat patients in clinical trials, hopefully within two years.”